14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ACAD vs TAX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over TAX (TAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACAD carries a Unified Composite Score of 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin), whereas TAX carries 47.5/100 (HOLD) at $28.09 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While TAX currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. ACAD 44.8/100 HOLD), ACAD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (+22.8% vs. N/A YoY).
Technical & Structure Timing Caution: ACAD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2); meanwhile TAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACAD vs TAX. Trailing 12-month operating profitability (ACAD 10.2% vs TAX N/A) and valuation multiples (ACAD 15.8x vs TAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ACAD vs TAX Key Questions & Quantitative Answers
As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over TAX (TAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACAD carries a Unified Composite Score of 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin), whereas TAX carries 47.5/100 (HOLD) at $28.09 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While TAX currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. ACAD 44.8/100 HOLD), ACAD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (+22.8% vs. N/A YoY). Technical & Structure Timing Caution: ACAD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2); meanwhile TAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ACAD leads the Growth & Scale pillar: ACAD posts +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin), compared with TAX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ACAD generates $1.20B in USD-normalized revenue versus N/A for TAX. In operating R&D and SG&A reinvestment, ACAD deploys 53.7% of Rev ($646M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TAX.
ACAD screens cheaper on headline valuation multiples. ACAD trades at 15.8x Forward P/E, 8.3x Trailing P/E, N/M PEG, and 2.3x EV/Revenue (15.0% FCF margin), whereas TAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACAD (31.4% ROE) versus TAX (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, ACAD carries 41.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 71.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.15β · 90% Vol realized risk). By comparison, TAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.07β · 27% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.